Revance Therapeutics Inc (RVNC)
2.82
-0.15
(-5.05%)
USD |
NASDAQ |
Jun 14, 16:00
2.81
-0.01
(-0.35%)
After-Hours: 20:00
Revance Therapeutics Research and Development Expense (Quarterly): 14.39M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.39M |
| December 31, 2023 | 20.37M |
| September 30, 2023 | 13.06M |
| June 30, 2023 | 22.81M |
| March 31, 2023 | 17.53M |
| December 31, 2022 | 19.54M |
| September 30, 2022 | 26.10M |
| June 30, 2022 | 24.91M |
| March 31, 2022 | 30.73M |
| December 31, 2021 | 29.47M |
| September 30, 2021 | 30.10M |
| June 30, 2021 | 29.44M |
| March 31, 2021 | 27.25M |
| December 31, 2020 | 29.77M |
| September 30, 2020 | 29.13M |
| June 30, 2020 | 27.10M |
| March 31, 2020 | 39.79M |
| December 31, 2019 | 27.49M |
| September 30, 2019 | 25.85M |
| June 30, 2019 | 25.53M |
| March 31, 2019 | 24.00M |
| December 31, 2018 | 25.53M |
| September 30, 2018 | 21.85M |
| Date | Value |
|---|---|
| June 30, 2018 | 22.87M |
| March 31, 2018 | 22.24M |
| December 31, 2017 | 21.00M |
| September 30, 2017 | 21.64M |
| June 30, 2017 | 18.31M |
| March 31, 2017 | 19.41M |
| December 31, 2016 | 12.53M |
| September 30, 2016 | 10.30M |
| June 30, 2016 | 15.19M |
| March 31, 2016 | 12.36M |
| December 31, 2015 | 14.96M |
| September 30, 2015 | 13.02M |
| June 30, 2015 | 10.30M |
| March 31, 2015 | 9.254M |
| December 31, 2014 | 9.129M |
| September 30, 2014 | 8.60M |
| June 30, 2014 | 8.11M |
| March 31, 2014 | 7.551M |
| December 31, 2013 | 6.239M |
| September 30, 2013 | 6.284M |
| June 30, 2013 | 7.782M |
| March 31, 2013 | 7.527M |
| December 31, 2012 | 16.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
13.06M
Minimum
Sep 2023
39.79M
Maximum
Mar 2020
25.52M
Average
26.60M
Median
Research and Development Expense (Quarterly) Benchmarks
| AbbVie Inc | 1.939B |
| Design Therapeutics Inc | 9.801M |
| Humacyte Inc | 21.26M |
| Context Therapeutics Inc | 1.973M |
| AN2 Therapeutics Inc | 14.66M |